IDH mutations as biomarkers for zotiracillin therapy
Personalized use of zotispicillin for cancer treatment by detecting IDH1 or IDH2 mutation status solves the problem of difficult to predict therapeutic efficacy and identifying beneficiary patients in the prior art, and achieves more efficient cancer treatment.
CN119997940APending Publication Date: 2025-05-13李想 +2
0 Cites 0 Cited by
Patent Information
- Application Number
- CN202380071050.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-08-10
- Filing Date
- 2023-08-09
- Publication Date
- 2025-05-13
AI Technical Summary
Technical Problem
The prior art is difficult to effectively predict the efficacy of zotiracillin in anti-cancer treatment and it is difficult to identify patients who benefit most from the chemotherapeutic agent.
Method used
By detecting the presence of isocitrate dehydrogenase (IDH1 or IDH2) mutation status in the patient's tissue sample, if present, the treatment is performed using a combination of drugs containing zotiracillin.
Benefits of technology
Personalized treatment for cancer patients is achieved, and the treatment effect of cancers containing IDH1 or IDH2 mutations is improved.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided are methods of using isocitrate dehydrogenase (IDH1 and IDH2) mutations to select cancer patients and treat with zotiracillin (TG02) therapies, e.g., to treat cancer, such as glioma, myeloblastoma, soft osteosarcoma, cholangioma, AML, astrocytoma, and the like, as a single agent in combination with other chemotherapeutic agents.
Need to check novelty before this filing date? Find Prior Art